Amherst receives grant funds to protect town drinking water
AMHERST, Mass. (WWLP) – The town of Amherst is one of five communities in Massachusetts that received funding from the Healey administration through the Drinking Water Supply Protection program.
The Healey administration announced on Friday that the Executive Office of Energy and Environmental Affairs (EEA) will provide over $1 million in grant funding to protect drinking water resources in the state. Five cities and towns were selected to receive funds, allowing these communities to purchase land to maintain the safety and quality of drinking water for residents.
Two Springfield golf courses receive $6M in clubhouse upgrades
'This funding is a critical step in ensuring that our communities have access to safe, clean drinking water,' said EEA Secretary Rebecca Tepper. 'By investing in land protection, we are not only safeguarding our vital water resources but also enhancing the quality of life for residents who rely on these resources for health and recreation.'
All land secured through funds from the Drinking Water Supply Protection Program will be designated protected open space under Article 97 of the Massachusetts Constitution. The town of Amherst was awarded $218,820 in grant funds to purchase an over 50-acre wooded property in Pelham.
The purchase of this property, adjacent to designated Watershed Protection Land, will protect designated Zone A surface water that contributes to the Pelham Reservoir System. Approximately one-third of Amherst's drinking water comes from the reservoir system, and it will now receive greater protection and directly benefit public health.
Other communities receiving grant funds through the program are Haverhill, Falmouth, Amesbury, and Cambridge.
WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc.
Yahoo
4 hours ago
- Yahoo
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
All-New Parlee Z-Zero GT is Slimmer, Lighter & Faster
Parlee is known for making great road bikes. Some of the best, in fact. So it's no small thing when they say their all-new Z-Zero GT road bike is the best they've ever made. It's a whopping 187g lighter than its predecessor, coming in under 900g for the frame. And it's faster, with a new layup that's stiffer where power transfer is key, but compliant and comfortable where it matters for traction and comfort. And it fits up to 40mm tires… a combo that makes it faster over anything you throw at it. Which is all well and good, but what about… Slimmer? The Z-Zero has been Parlee's flagship road bike since Bob Parlee founded the company 25 years ago. Designed long before disc brakes and 28mm tires were the norm, it had those classic road bike lines, slender tubes, and an aesthetic that retrogrouches love. Over the years, the bike got better, lightened up, and switched to disc brakes, but it kept those slim lines thanks to external routing. But, times (and tastes) have changed, and discerning riders want that sleek, aero look of integrated stealth routing. But, some also want to maintain a classic look. And Parlee won't do anything that sacrifices ride quality. So, the new Z-Zero GT pays homage to its pedigree while going full modern on routing, tire clearance, and drivetrain compatibility. And it started with a new fork, their first-ever designed, developed, and manufactured 100% in house in Beverly, MA. Parlee's GT has a head tube nearly as slim as the standard Z-Zero thanks to a proprietary fork with a D-shaped steerer tube. This lets them use a standard headset for 1.125″ to 1.25″ tapered steerers, keeping the top of the headtube slim and use normal headsets. That keeps it compatible with all manner of stems and handlebars, too, so you can pick from a wide variety of options for complete builds. If you'd like to see more about the fork, check out our factory tour for closeup photos and a look at how they make it. Taking everything they've learned over 25 years, the new frame is 187g lighter than the Z-Zero it's replacing. Claimed frame weight is under 900g (893g for size 53, to be exact), and for the first time, this top model will be offered in stock sizing, too. More on that below. The rear dropouts and chainstay structure are completely redesigned to improve stiffness and work with UDH hangers, letting you run the bike with all of SRAM's 1x and 2x road and gravel groups, as well as future proofing it for next-gen Transmission drivetrains. Naturally, it's also fully compatible with Shimano and Campagnolo drivetrains, too. The frame's layup and geometry is optimized around ride quality, Parlee's calling card. If you haven't ridden a Parlee, it's hard to describe, but it just feels right. Check our review of the RZ7 for an example. For this bike, they dropped the bottom bracket ~10mm to keep your center of gravity lower for carving high speed corners, particularly on the descents. Spec highlights include: Up to 40mm tire clearance T47 bottom bracket All-carbon dropouts Sub-900g frame Ceramicspeed bottom bracket & SLT headset The Z-Zero GT is Parlee's first Z-series bike to be offered in stock sizes, and they've got 12 to choose from, with either Race or Sport fit. The geos are based on 25 years of fit data, and it's a lot of data because they request a bike fit for every customer so they can help choose the right components. Which means, no matter what build you go with, the GT's cockpit, crank length, and everything else will be handpicked to fit you and your riding style…there's no truly 'stock' build here, it's all built to order to give you exactly what you want. The Z-Zero GT comes in 20 standard colors, but you can also have it custom painted. Or, order it with their Nude finish, which is bare carbon, pretty much straight out of the mold, then waxed to protect it. That's the lightest option, and it's how they ship their Ouray and Taos production bikes, too. There's also an 'extended paint' option that color-matches the cockpit, seatpost, bottle cages, and headset spacers. The new Z-Zero GT frames start at $12,490. Complete bikes start at $16,490 for Force or Ultegra level builds and run up to $22,990 for a range topping bike with the new Campagnolo Super Record 13 drivetrain. Dealer pre-orders have already filled the production queue, and those start shipping in August. Parlee says current estimated delivery date for new orders is November 2025. A special, extremely limited Z-Zero GT 25th Anniversary Edition will also be available around November with a highly curated, bespoke build using the best components and accessories available. The post All-New Parlee Z-Zero GT is Slimmer, Lighter & Faster appeared first on Bikerumor.
